Sudarshan Pharma Achieves GMP Compliance and ISO 9001:2015 Certification for Hyderabad API Facility

Sudarshan Pharma Industries Limited has officially achieved two significant regulatory milestones for its facility located in Medchal, Hyderabad. The company received a Certificate of Compliance for Good Manufacturing Practice (GMP) from UK Certification & Inspection Limited, specifically covering the manufacturing of API Intermediates and Active Pharmaceutical Ingredients (APIs). Validated on February 12, 2026, this certification (Number: UQ-2026021213) confirms that the plant’s operational standards and production environments meet the rigorous safety and quality norms required for pharmaceutical manufacturing. The certificate remains valid until February 2029, subject to successful annual surveillance audits scheduled for 2027 and 2028.

In addition to the GMP compliance, the Hyderabad facility has been awarded the ISO 9001:2015 certification by Staunchly Management and System Services Private Limited. This certification confirms that the site’s Quality Management System (QMS) conforms to international standards for the scope of manufacturing API Intermediates and APIs. By securing both GMP and ISO 9001:2015 credentials, Sudarshan Pharma demonstrates a standardised approach to process consistency and quality control at Plot No. D 22, IDA-Medchal. These dual certifications serve as formal recognition of the facility's technical capabilities and its adherence to global administrative and manufacturing protocols.

About the Company

Sudarshan Pharma Industries Ltd., incorporated in 2008, is a Mumbai-based company specialising in the manufacturing of Active Pharmaceutical Ingredients (APIs) and pharmaceutical items, alongside trading in chemicals and solvents. They offer a diverse portfolio, from bulk chemicals and intermediates to finished formulations, with numerous products registered under their "R" trademark, including popular brands like Love Birds and Metfocal. The company operates both in India and international markets, including exports to countries in Southeast Asia, the Middle East and North Africa.

According to the Quarterly Results, the net sales increased by 16 per cent to Rs 168.01 crore in Q3FY26 compared to Q3FY25. The company reported a net profit of Rs 4.36 crore in Q3FY26, an increase of 51 per cent compared to Q3FY25. For nine-month results, the net sales increased by 40 per cent to Rs 482.14 crore and net profit increased by 67 per cent to Rs 12.58 crore in 9MFY26 compared to 9MFY25. In its annual results, the net sales increased by 9 per cent to Rs 505 crore and net profit increased by 45 per cent to Rs 16 crore in FY25 compared to FY24.

The company has a market cap of over Rs 600 crore and has delivered a good profit growth of 70 per cent CAGR over the last 5 years. This pharma company’s stock falls under SME with a lot size of 4,000 shares. The stock is up by 38 per cent from its 52-week low of Rs 18.50 per share and has given multibagger returns of over 260 per cent in 2 years.

Disclaimer: The article is for informational purposes only and not investment advice.